Navigation Links
Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
Date:12/4/2008

WALTHAM, Mass., Dec. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that novel anticoagulants that include emerging drugs from Boehringer Ingelheim, Bayer/Johnson & Johnson and Bristol-Myers Squibb/Pfizer, will garner more than three-quarters of the atrial fibrillation drug market by 2017.

The new Pharmacor report entitled Atrial Fibrillation finds that the most promising emerging oral anticoagulants are Boehringer Ingelheim's Pradaxa/Rendix, Bayer/Johnson & Johnson's Xarelto and Bristol-Myers Squibb/Pfizer's apixaban, which will each garner peak-year blockbuster sales of more than $1 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. New anticoagulants, which will largely displace the use of the vitamin K antagonist drug class, will garner 76 percent of the atrial fibrillation market in 2017, owing to the strong potential each agent has in preventing stroke.

The report finds that the emergence and success of novel oral anticoagulants, combined with the launch and extensive uptake of Sanofi-Aventis's antiarrhythmic drug Multaq, will drive 15 percent annual market growth from 2007 to 2012. Market growth from 2012 to 2017 will then increase to a robust 27 percent annually, driving overall sales of atrial fibrillation therapies to $5.4 billion in 2017, compared to just over $800 million in 2007.

"Multaq, with its favorable efficacy and safety profile and its ability to reduce hospitalization and prevent stroke, will launch in 2009 and its arrival will enjoy wide acceptance by physicians," said Samira Benyoucef, Ph.D., analyst at Decision Resources. "Additionally, the introduction of more convenient and safe novel anticoagulants that offer advantages over existing agents will fuel significant expansion of the atrial fibrillation market over the next decade."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

    All company, brand, or product names contained in this document may be
       trademarks or registered trademarks of their respective holders.

     For more information, contact:

     Decision Resources                         Decision Resources, Inc.
     Christopher Comfort                        Elizabeth Marshall
     781-296-2597                               781-296-2563
     ccomfort@dresources.com                    emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published author, ... his wife, Anna Marie. He and his wife are the proud parents of four ... of “Shadow and Substance.” , “Love, the agape kind, is seen as more than ...
(Date:3/23/2017)... NC & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... public health emergency and now estimates that there could be four million Zika-related cases ... growing epidemics to date with numbers of US cases reported per year skyrocketing to ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... services to their communities, 16 more public health departments have been awarded national ... bring another 4.5 million people into the expanding network of communities across the ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the ... huge impact on businesses and individual consumers alike. Laboratories can maximize their profit ... value anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017  Mirabilis Medical, a Seattle ... non-invasive surgery, announced today CE Mark authorization for ... uterine fibroids throughout the European Union.  The company ... the US Food and Drug Administration to begin ... the United States.  The Mirabilis System combines high-speed ...
(Date:3/24/2017)... and GENEVA , March 24, 2017 ... Tuberculosis Day revitalizes efforts to develop sutezolid as effective ... World Tuberculosis Day, TB Alliance and the Medicines Patent ... development of sutezolid, an antibiotic drug candidate which demonstrated ... the development of sutezolid in combination with other TB ...
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: